Compare AbCellera Biologics Inc (ABCL) vs YieldMax Magnificent 7 Fund of Option Income ETFs (YMAG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbCellera Biologics Inc vs YieldMax Magnificent 7 Fund of Option Income ETFs — how do they compare? AbCellera Biologics Inc trades at $9.23 (market cap $2.99B), while YieldMax Magnificent 7 Fund of Option Income ETFs trades at $11.41. The key difference: AbCellera Biologics Inc is trading nearer its 52-week high, YieldMax Magnificent 7 Fund of Option Income ETFs nearer its low. Which is the better fit depends on your goals.
| ABCL | YMAG | |
|---|---|---|
Market Cap | $2.99B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $9.76 | $15.98 |
52-Week Low | $2.78 | $10.76 |
Enterprise Value | $2.58B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) surged 34.78% to $9.34, driven by positive Phase 2 trial results for its menopause drug ABCL635. Despite negative net income margins and cash burn, analyst consensus is strongly bullish with a $15.50 price target. The stock shows a bullish technical trend, with support at $8 and resistance at $10, though RSI levels indicate overbought conditions.
The outlook hinges on ABCL635's clinical progress and future revenue potential, but high valuation ratios and persistent losses pose significant risks. Investor sentiment is optimistic due to recent drug trial success, yet the company must demonstrate a path to profitability to justify current market enthusiasm.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About YieldMax Magnificent 7 Fund of Option Income ETFs
YMAG is an actively managed 'fund of funds' that provides equal-weighted exposure to the seven YieldMax ETFs tracking the 'Magnificent 7' tech giants (Apple, Microsoft, Alphabet, Amazon, Nvidia, Meta, and Tesla). It seeks to generate high current income by harvesting option premiums across these leaders, offering a streamlined way to access concentrated tech volatility in an income-producing format.
Read more on YMAG →
